A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Oklahoma
Eli Lilly and Company
Blueprint Medicines Corporation
Inspirna, Inc.
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
National Institutes of Health Clinical Center (CC)
Oncology Institute of Southern Switzerland
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sanofi